Down regulation of CAII is associated with tumor differentiation and poor prognosis in patients with pancreatic cancer

Journal of Surgical Oncology

Volumn 107, Issue 5, 2013, Pages 536-543

  Sheng, Weiwei ^a   Dong, Ming ^a   Zhou, Jianping ^a   Li, Xin ^a   Dong, Qi ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b People's Hospital of Liaoning Province   (China)

Author keywords

acetazolamide; CAI; CAII; CAIX; p53; pancreatic cancer; prognostic biomarker

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; PROTEIN P53;

APOPTOSIS; ARTICLE; BIOASSAY; CANCER CELL; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER THERAPY; CANCER TISSUE; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION;

ACETAZOLAMIDE; APOPTOSIS; CARBONIC ANHYDRASE I; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASE INHIBITORS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84875262494     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23282     Document Type: Article

References (34)

1. Fry LC, Mönkemüller K, Malfertheiner P,: Molecular markers of pancreatic cancer: Development and clinical relevance. Langenbecks Arch Surg 2008; 393: 883-890.
2. Supuran CT,: Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-181.
3. Kuo WH(a), Yang SF, Hsieh YS, et al.: Differential expression of carbonic anhydrase isoenzymes in various types of anemia. Clin Chim Acta 2005; 351: 79-86.
4. Chiang WL, Chu SC, Yang SS, et al.: The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer. Cancer Lett 2002; 188: 199-205.
5. Leppilampi M, Koistinen P, Savolainen ER, et al.: The expression of carbonic anhydrase II in hematological malignancies. Clin Cancer Res 2002; 8: 2240-2245.
6. Kuo WH(b), Chiang WL, Yang SF, et al.: The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life Sci 2003; 73: 2211-2223.
7. Bekku S, Mochizuki H, Yamamoto T, et al.: Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer. Hepatogastroenterology 2000; 47: 998-1001.
8. Kivela AJ, Saarnio J, Karttunen TJ, et al.: Differential expression of cytoplasmic carbonic anhydrases,CA I and II,and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and incolorectal tumors. Dig Dis Sci 2001; 46: 2179-2186.
9. Haapasalo J, Nordfors K, Järvelä S, et al.: Carbonic anhydrase II in the endothelium of glial tumors: A potential target for therapy. Neuro Oncol 2007; 9: 308-313.
10. Morton JP, Timpson P, Karim SA, et al.: Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2010; 107: 246-251.
11. Dong M, Nio Y, Yamasawa K, et al.: p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 2003; 82: 111-120.
12. Yamasawa K, Nio Y, Dong M, et al.: Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. Clin Cancer Res 2002; 8: 2563-2569.
13. Bister V, Skoog T, Virolainen S, et al.: Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma. Mod Pathol 2007; 20: 1128-1140.
14. Yonezawa S, Byrd JC, Dahiya R, et al.: Differential mucin gene expression in human pancreatic and colon cancer cells. Biochem J 1991; 276: 599-605.
15. Dong M, Dong Q, Zhang H, et al.: Expression of Gadd45a and p53 proteins in human pancreatic cancer: Potential effects on clinical outcomes. J Surg Oncol 2007; 95: 332-336.
16. Shah AN, Summy JM, Zhang J, et al.: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14: 3629-3637.
17. Sung CO, Han SY, Kim SH,: Low expression of claudin-4 is associated with poor prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol 2011; 18: 273-281.
18. Parkkila AK, Herva R, Parkkila S, et al.: Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumors. Histochemical J 1995; 27: 282-974.
19. Parkkila S, Parkkila AK, Juvonen T, et al.: Distribution of the carbonic anhydrase isoenzymes I, II, and VI in the human alimentary tract. Gut 1994; 35: 646-650.
20. Parkkila S, Parkkila AK, Juvonen T, et al.: Immunohistochemical demonstration of the carbonic anhydrase isoenzymes I and II in pancreatic tumors. Histochem J 1995; 27: 133-138.
21. Chen J, Kremer CS, Bender TP,: The carbonic anhydrase I locus contains a c-Myb target promoter and modulates differentiation of murine erythroleukemia cells. Oncogene 2006; 25: 2758-2772.
22. Frazier ML, Lilly BJ, Wu EF, et al.: Carbonic anhydrase II gene expression in cell lines from human pancreatic adenocarcinoma. Pancreas 1990; 5: 507-514.
23. Parkkila S, Lasota J, Fletcher JA, et al.: Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol 2010; 23: 743-750.
24. Graziano F, Cascinu S, Staccioli MP, et al.: Potential role and chronology of abnormal expression of the deleted in colon cancer (DCC) and the p53 proteins in the development of gastric cancer. BMC Cancer 2001; 1: 9.
25. Radovanović D, Knezević M, Canović D, et al.: Correlation between p53 expression and clinical-pathological characteristics of gastric cancer. Vojnosanit Pregl 2011; 68: 832-836.
26. Nishimori I, Fujikawa-Adachi K, Onishi S, et al.: Carbonic anhydrase in human pancreas: Hypotheses for the pathophysiological roles of CA isozymes. Ann NY Acad Sci 1999; 880: 5-16.
27. Juhász M, Chen J, Lendeckel U, et al.: Expression of carbonic anhydrase IX in human pancreatic cancer. Aliment Pharmacol Ther 2003; 18: 837-846.
28. Turkmen H, Durgun M, Yilmaztekin S, et al.: Carbonic anhydrase inhibitors. Novel sulfanilamide/AZ derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX. Bioorg Med Chem Lett 2005; 15: 367-372.
29. Supuran CT, Scozzafava A,: Carbonic anhydrase inhibitors part 94. 1,3,4-thiadiPDACole-2-sulfonamide derivatives as anti-tumor agents? Eur J Med Chem 2000; 35: 867-874.
30. Cianchi F, Vinci MC, Supuran CT, et al.: Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. J Pharmacol Exp Ther 2010; 334: 710-719.
31. Parkkila S, Rajaniemi H, Parkkila AK, et al.: Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA 2000; 97: 2220-2224.
32. Kivela AJ, Parkkila S, Saarnio J, et al.: Expression of trans-membrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumors. Histochem Cell Biol 2000; 114: 197-204.
33. McDonald PC, Winum JY, Supuran CT, et al.: Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 2012; 3: 84-97.
34. Monti SM, Supuran CT, De Simone G,: Carbonic anhydrase IX as a target for designing novel anticancer drugs. Curr Med Chem 2012; 19: 821-830.